Holen Sie sich die Stockscreener-App
1.95
2.63%
0.05
Handel nachbörslich:
1.92
-0.03
-1.54%
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus
BioXcel Therapeutics (BTAI) Gains Patent Approval, Price Target Affirmed | BTAI Stock News - GuruFocus
BioXcel Granted Patent for Dexmedetomidine Use - TipRanks
BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent - Investing.com
BioXcel wins USPTO nod; 14th Igalmi patent secures exclusivity to 2043 | BTAI SEC FilingForm 8-K - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress - Insider Monkey
12 Best Fundamentally Strong Penny Stocks to Invest in - Insider Monkey
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
NIP Group, Hyatt, BioXcel Therapeutics - TradingView
BioXcel Therapeutics rises on positive schizophrenia drug trial recommendation - TradingView
Why BioXcel Therapeutics Is Rising In Pre-market? - Nasdaq
BioXcel’s BXCL501 agitation treatment trial continues after safety review By Investing.com - Investing.com Canada
BioXcel’s BXCL501 agitation treatment trial continues after safety review - Investing.com
Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia - TradingView
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - TradingView
Bioxcel Therapeutics Plunges 11.71% Post Reverse Split - AInvest
Is BioXcel Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
BioXcel stock price target raised to $8 from $3 at H.C. Wainwright - Investing.com India
BioXcel Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent
BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN
BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus
Class Suit Against AI Drugmaker Back On After Mediation Fails - Law360
BTAIBioXcel Therapeutics Provides Clinical and Business Update - mx.advfn.com
BioXcel’s Phase 3 trial of BXCL501 continues as advised by DSMB - Investing.com India
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq L - GuruFocus
BioXcel Therapeutics granted Nasdaq extension - Investing.com Australia
BioXcel granted an extension for compliance by Nasdaq - Hartford Business Journal
BioXcel Therapeutics granted Nasdaq extension By Investing.com - Investing.com South Africa
BTAI's Phase 3 Trial for BXCL501 Advances Unhindered by Safety Concerns | BTAI Stock News - GuruFocus
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated wit - GuruFocus
Bioxcel Therapeutics Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirement - marketscreener.com
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq Listing - GuruFocus
BioXcel's Breakthrough At-Home Agitation Drug Clears Critical Safety Review, First FDA Approval Possible - Stock Titan
BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | B - GuruFocus
BioXcel Granted Nasdaq Compliance Extension Until September - TipRanks
BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | BTAI Stock News - GuruFocus
BioXcel Gets Critical Nasdaq Reprieve: 4-Month Extension as Phase 3 Trial Results Near - Stock Titan
BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN
Can a $10,000 Investment in SoundHound AI Turn Into $1 Million by 2035? - The Globe and Mail
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments - TipRanks
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | BTAI Stock News - GuruFocus
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
3.40%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):